Table 1 Subject Characteristics at the Entry Visit
From: Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy
Characteristic | Value |
|---|---|
Age, years, median (range) | 41.5 (23–64) |
Male, n (%) | 39 (78%) |
Race, n (%) White, not Hispanic | 33 (66%) |
Black, not Hispanic | 10 (20%) |
Hispanic | 4 (8%) |
Other | 3 (6%) |
Years of education, median (range) | 13 (9–18) |
NPZ4, mean (standard deviation) | -0.46 (0.72) |
Current antiretroviral use, n (%) | 33 (66%) |
ARVs with good CNS penetration, median (range) | 3 (0–4) |
Two or more ARVs with good CNS penetration, n (%) | 28 (85%) |
Peripheral blood CD4+ T cells/ul, median (range) | 467 (3–1016) |
Plasma HIV RNA (49 subjects) | |
Detectable n (%) | 29 (58%) |
RNA log copies/ml in those with detectable plasma HIV RNA, median (range) | 3.50 (1.82–5.48) |
CSF WBC | |
WBC > 5/ul, n (%) | 15 (30%) |
CSF WBC in those with > 5/ul, median, (range) | 13 (7–51) |
CSF HIV RNA | |
Detectable, n (%) | 17 (34%) |
CSF HIV RNA log copies/ml in those with detectable CSF HIV RNA, median (range) | 2.92 (1.71–4.08) |